Amylin analogs for the treatment of obesity without diabetes: present and future.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Amylin analogs for the treatment of obesity without diabetes: present and future.
- Published In:
- Expert review of clinical pharmacology, 1-9 (2024)
- Authors:
- Panou, Theodoros(2), Gouveri, Evanthia(3), Popovic, Djordje S(7), Papanas, Nikolaos
- Database ID:
- RPEP-09024
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-09024APA
Panou, Theodoros; Gouveri, Evanthia; Popovic, Djordje S; Papanas, Nikolaos. (2024). Amylin analogs for the treatment of obesity without diabetes: present and future.. Expert review of clinical pharmacology, 1-9. https://doi.org/10.1080/17512433.2024.2409403
MLA
Panou, Theodoros, et al. "Amylin analogs for the treatment of obesity without diabetes: present and future.." Expert review of clinical pharmacology, 2024. https://doi.org/10.1080/17512433.2024.2409403
RethinkPeptides
RethinkPeptides Research Database. "Amylin analogs for the treatment of obesity without diabetes..." RPEP-09024. Retrieved from https://rethinkpeptides.com/research/panou-2024-amylin-analogs-for-the
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.